Fresenius Kabi USA Issues Voluntary Nationwide Recall of Benztropine Mesylate Injection, USP 2 mg/2 mL (1 mg/mL), in 2 mL Single Dose Vials
7/1/2013 8:53:32 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi USA is voluntarily recalling four lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the potential presence of glass particles (glass delamination) in the vials. This recall is being conducted to the user level.
Help employers find you! Check out all the jobs and post your resume.
comments powered by